KCM
KROS icon

Kennedy Capital Management’s Keros Therapeutics KROS Stock Holding History

Kennedy Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-58,119
Closed -$2.34M – 693
2023
Q2 		$2.34M Buy
58,119
+34,239
+143% +$1.5M 0.05% 430
2023
Q1 		$1.02M Buy
23,880
+390
+2% +$19.7K 0.03% 485
2022
Q4 		$1.13M Sell
23,490
-16
-0.1% -$747 0.03% 477
2022
Q3 		$884K Sell
23,506
-23,676
-50% -$821K 0.03% 496
2022
Q2 		$1.3M Buy
47,182
+844
+2% +$37K 0.04% 447
2022
Q1 		$2.52M Sell
46,338
-367
-0.8% -$18.8K 0.06% 417
2021
Q4 		$2.73M Buy
46,705
+2,918
+7% +$146K 0.06% 419
2021
Q3 		$1.73M Sell
43,787
-679
-2% -$24.2K 0.04% 482
2021
Q2 		$1.89M Sell
44,466
-23,514
-35% -$1.27M 0.04% 482
2021
Q1 		$4.18M Buy
+67,980
New +$4.31M 0.08% 408

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $22.1B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return